rinvecalinase alfa — Interim data
Q1 2027
Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027Source filing
DMAC biotech catalysts & pipeline
DIAMEDICA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
rinvecalinase alfa — Conference presentation
September
Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in SeptemberSource filing